Results 181 to 190 of about 15,923 (217)
Treat to Target in Axial Spondyloarthritis
Rheumatic Disease Clinics of North America, 2019 This article discusses treat-to-target strategies in axial spondyloarthritis and current status. Treatment ranging from nonsteroidal anti-inflammatory drugs to biologic and other disease-modifying drugs is discussed in the context of treat-to-target.
Nikiphorou, E., Baraliakos, Xenofon
openaire +4 more sources
Treatment of Axial Spondyloarthritis: What Does the Future Hold? [PDF]
Current Rheumatology Reports, 2020 Purpose of Review: To provide a summary of the recent and expected developments related to the treatment of axial spondyloarthritis. Recent Findings: An increasing number of interleukin-17 blocking agents show efficacy in axial spondyloarthritis ...
Denis Poddubnyy +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Axial Spondyloarthritis in Japan
Current Rheumatology Reports, 2022The differences in the epidemiology and management of patients with axial spondyloarthritis (axSpA) among regions and countries largely depend on the positivity of human leukocyte antigen (HLA)-B27 and the health care system. This review article focused on axSpA in Japan, where the prevalence of HLA-B27 is extremely low (0.3%) and the universal health ...
Hideto Kameda +5 more
openaire +2 more sources
The Lancet, 2013
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease predominantly of the sacroiliac joint (SIJ) and the spine. It starts normally in the second decade of life and has a slight male predominance. The prevalence is between 0.2% and 0.8% and is strongly dependent on the prevalence of HLA-B27 in a given population.
Joachim, Sieper, Denis, Poddubnyy
openaire +2 more sources
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease predominantly of the sacroiliac joint (SIJ) and the spine. It starts normally in the second decade of life and has a slight male predominance. The prevalence is between 0.2% and 0.8% and is strongly dependent on the prevalence of HLA-B27 in a given population.
Joachim, Sieper, Denis, Poddubnyy
openaire +2 more sources
, 2019 From the Publisher: Focusing on the key essentials you need to know, Axial Spondyloarthritis provides a quick, expert overview of axSpA from a clinical perspective. This concise resource by Drs.
Adam Berlinberg, Kristine A. Kuhn
openaire +2 more sources
Mimics of axial spondyloarthritis
Current Opinion in Rheumatology, 2019Purpose of reviewAxial spondyloarthritis (AxSpA) is a distinct clinical entity with characteristic clinical and radiographic features; however, a multitude of other metabolic, infectious and inflammatory disorders mimic it both clinically and radiographically.Recent findingsWe present in this review article recent updates about the various disease ...
Sali, Merjanah +2 more
openaire +2 more sources
2023
Abstract Spondyloarthritis (SpA) is a blanket term encompassing a family of chronic inflammatory joint diseases that commonly involve the SI joints, spine, and the limbs, and share many clinical features, including frequent association with inflammation affecting the eyes, the gut, and the skin.
Xenofon Baraliakos +2 more
openaire +2 more sources
Abstract Spondyloarthritis (SpA) is a blanket term encompassing a family of chronic inflammatory joint diseases that commonly involve the SI joints, spine, and the limbs, and share many clinical features, including frequent association with inflammation affecting the eyes, the gut, and the skin.
Xenofon Baraliakos +2 more
openaire +2 more sources
Axial Imaging in Spondyloarthritis
Rheumatic Disease Clinics of North AmericaImaging plays a crucial role in diagnosing and forecasting treatment outcomes in axial spondyloarthritis. Conventional radiography may overlook patients in the initial stages of the disease, while MRI is sensitive in identifying inflammation early on. Computed tomography reliably detects structural abnormalities. Practicing rheumatologists must possess
Vishnu, Mohan, Mark C, Hwang
openaire +2 more sources
Biomarkers in axial spondyloarthritis
Current Opinion in Rheumatology, 2015To assess the literature for biomarker validation studies that address key unmet needs related to the evaluation and management of patients with axial spondyloarthritis (SpA). This review focused on biomarkers facilitating early diagnosis and reflecting disease activity, structural damage on radiography, and clinical response to major therapies.Early ...
openaire +2 more sources
Treatment of axial spondyloarthritis: an update
Nature Reviews Rheumatology, 2022Diagnosis and management of axial spondyloarthritis (axSpA) has vastly improved over the past two decades. With advances in the discernment of immunopathogenesis of this disease, new therapies have become available, which are associated with substantial improvement in symptoms, signs and quality of life.
Abhijeet Danve, Atul Deodhar
openaire +2 more sources